Status:
COMPLETED
Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Dyslipidemias
Eligibility:
All Genders
19+ years
Brief Summary
A Cohort Study for Comparison of Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration and Statin Prescription Patterns in Patients With Dyslipidemia in Korea.
Detailed Description
The main objective of this study is to evaluate the effect of reducing LDL-C levels after 12 months of administration of Statin Monotherapy or Rosuzet Tab.(Rosuvastatin/Ezetimibe) in patients with dys...
Eligibility Criteria
Inclusion
- Age≥19
- Subject who is taking or is scheduled to take Statins therapy or Rosuzet Tab.
- Not diagnosed with diabetes
- Subject who can written informed consent voluntarily
- Subject can continue to participate for 12 months on Study
Exclusion
- Patients for whom use of Rosuzet Tab. and Statin therapy is prohibited (e.g. patient who are hypersensitive to the main or compositional component of this drug, patient with active liver disease, patient with severe renal failure, patient using combinations with cyclosporin)
- A pregnant or nursing woman
Key Trial Info
Start Date :
June 14 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 29 2019
Estimated Enrollment :
5717 Patients enrolled
Trial Details
Trial ID
NCT04829149
Start Date
June 14 2016
End Date
August 29 2019
Last Update
April 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Pharmaceutical Company Limited
Seoul, South Korea, 05545